Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Acquires $24,750.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,800 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was acquired at an average cost of $13.75 per share, with a total value of $24,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,550,002 shares in the company, valued at $76,312,527.50. The trade was a 0.03 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $12.38 on Friday. The company has a market capitalization of $162.74 million, a PE ratio of -15.47 and a beta of 1.66. The stock has a fifty day moving average of $13.13 and a 200-day moving average of $14.10. Greenwich LifeSciences, Inc. has a one year low of $8.00 and a one year high of $21.44.

Institutional Investors Weigh In On Greenwich LifeSciences

Several hedge funds have recently modified their holdings of GLSI. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences in the 2nd quarter worth about $264,000. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences in the second quarter worth approximately $117,000. Garden State Investment Advisory Services LLC acquired a new stake in shares of Greenwich LifeSciences during the third quarter valued at approximately $253,000. State Street Corp raised its holdings in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Finally, Barclays PLC lifted its position in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.